ストックスクリーナーアプリを入手
95.16
0.61%
-0.69
前日終値:
$95.85
開ける：
$95.8
24時間の取引高:
195.24K
Relative Volume:
0.19
時価総額：
$22.89B
収益：
$3.13B
当期純損益:
$-381.72M
株価収益率:
-59.41
EPS:
-1.6017
ネットキャッシュフロー:
$-2.15B
1週間 パフォーマンス:
-1.51%
1か月 パフォーマンス:
-9.33%
6か月 パフォーマンス:
-10.87%
1年 パフォーマンス:
-18.47%
1日の値動き範囲:
$94.52
$95.88
1週間の範囲:
$94.52
$99.56
52週間の値動き範囲:
$81.20
$129.27
Biontech Se Adr Stock (BNTX) Company Profile
BNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
95.18 | 23.05B | 3.13B | -381.72M | -2.15B | -1.6017 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.81 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
708.36 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
893.67 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
410.36 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
195.05 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-05-29 | 開始されました | Goldman | Neutral |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-01-10 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2024-11-19 | 開始されました | Berenberg | Buy |
| 2024-11-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-11-08 | アップグレード | Goldman | Neutral → Buy |
| 2024-09-24 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-09-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-08-07 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-08-02 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-14 | 開始されました | Evercore ISI | In-line |
| 2024-02-23 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-05 | 開始されました | Oppenheimer | Perform |
| 2023-12-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-10-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-17 | アップグレード | Redburn | Neutral → Buy |
| 2022-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-08-17 | 開始されました | Cowen | Market Perform |
| 2022-07-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2021-12-16 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-08-11 | アップグレード | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-16 | ダウングレード | Redburn | Neutral → Sell |
| 2021-05-18 | 開始されました | Goldman | Neutral |
| 2021-05-11 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-08-03 | 再開されました | Berenberg | Buy |
| 2020-07-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-06-30 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 開始されました | H.C. Wainwright | Neutral |
| 2020-01-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-11-05 | 開始されました | Wolfe Research | Outperform |
| 2019-11-04 | 開始されました | Berenberg | Buy |
| 2019-11-04 | 開始されました | BofA/Merrill | Buy |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-11-04 | 開始されました | JP Morgan | Overweight |
| 2019-11-04 | 開始されました | SVB Leerink | Outperform |
| 2019-11-04 | 開始されました | UBS | Buy |
すべてを表示
Biontech Se Adr (BNTX) 最新ニュース
First Trust Advisors LP Has $35.28 Million Holdings in BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart - Seeking Alpha
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Benzinga
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech stock rises after promising lung cancer drug shows survival benefit By Investing.com - Investing.com South Africa
BioNTech stock rises after promising lung cancer drug shows survival benefit - Investing.com
Dodge & Cox Invests $93.42 Million in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s (BNTX) “Buy” Rating Reaffirmed at Jefferies Financial Group - Defense World
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules - Yahoo Finance
Scotia Capital Inc. Cuts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Validea's Top Health Care Stocks Based On Benjamin Graham12/1/2025 - Nasdaq
Groupama Asset Managment Buys 26,681 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Employees Retirement System of Texas Has $1.69 Million Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Legal & General Group Plc Boosts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Aristides Capital LLC Purchases 2,826 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE ADR Rises 3.0%, Outperforms Market - 富途牛牛
Edmond DE Rothschild Holding S.A. Raises Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s acquisition of CureVac nears completion as offer deadline approaches - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Purchased by CenterBook Partners LP - MarketBeat
AXQ Capital LP Acquires 1,073 Shares of Strategy Inc $MSTR - Defense World
Bank Julius Baer & Co. Ltd Zurich Lowers Stock Holdings in BioNTech SE Sponsored ADR $BNTX - Defense World
Allworth Financial LP Grows Stake in BioNTech SE Sponsored ADR $BNTX - Defense World
Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too? - Barchart.com
BioNTech Faces Strategic Crossroads as Pfizer Reduces Stake () - aktiencheck.de
Total debt per share of BioNTech SE Sponsored ADR – BER:22UA - TradingView
SG Americas Securities LLC Acquires 51,792 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ - Finviz
BioNTech’s Earnings Call: Progress Amid Challenges - MSN
Pfizer Scales Back Major Stake in BioNTech - Ad-hoc-news.de
BioNTech Shares Under Pressure as Key Investor Exits - AD HOC NEWS
Allianz SE Buys 5,080 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech Shares Face Pressure as Pfizer Cuts Stake () - aktiencheck.de
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up By Reuters - Investing.com
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Is BioNTech Stock Building Momentum for a Sustained Recovery? () - aktiencheck.de
BioNTech SE (BNTX) Stock Price, Trades & News - GuruFocus
BioNTech SE Reports Q3 2025 Financial Results - MSN
BioNTech Earnings: Steady Progress in Next-Generation Oncology Pipeline; Guidance Raised - Morningstar
BioNTech Q3 2025 Earnings Call Transcript - MarketBeat
BioNTech’s Promising Clinical Study: A New Hope for Advanced Solid Tumors? - MSN
BioNTech Faces Critical Earnings Test Amid Divergent Forecasts () - aktiencheck.de
BioNTech SE’s Promising Phase 3 Study on NSCLC Treatment: A Potential Game-Changer - TipRanks
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - MSN
BioNTech’s BNT116 Study: A New Hope for Advanced Lung Cancer? - MSN
BioNTech’s Promising PDAC Study: Market Implications and Progress - MSN
BioNTech’s Latest Clinical Study: A New Hope for Advanced Solid Tumors? - TipRanks
ETFs Investing in BioNTech SE Sponsored ADR Stocks - TradingView
BioNTech’s Latest Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - TipRanks
Bristol-Myers Squibb and BioNTech’s New Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Bristol-Myers Squibb and BioNTech Launch New Colorectal Cancer Study - TipRanks
Biontech Se Adr (BNTX) 財務データ
収益
当期純利益
現金流量
EPS
0.13%
0.80%
大文字化:
|
ボリューム (24 時間):